Option Compound Development Milestones Clause Samples
Option Compound Development Milestones. Provided that the option in Article 7 is exercised in full, for a Licensed Compound or Licensed Product containing an [* * *] Antibody, [* * *] Antibody, or [* * *] Antibody, Celgene shall also pay to Acceleron the amounts set forth below no later than [* * *] days after the earliest date on which the corresponding milestone event has first been achieved with respect to any such Licensed Compound or Licensed Product (for the avoidance of doubt, the milestones set forth below shall be payable separately with respect to a Licensed Compound or Licensed Product containing an [* * *] Antibody, an [* * *] Antibody or a [* * *] Antibody): [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] [* * *] $ [* * *] $ [* * *] The determination of whether a Clinical Trial or NDA falls within the oncology indication or non-oncology indication will be made in the same manner as provided in Section 5.2. For clarity, the milestone payments set forth in this Section 5.3 shall be paid only once for each indication for a Licensed Compound or Licensed Product the underlying Licensed Compound of which is an [* * *] Antibody, once for each indication for a Licensed Compound or Licensed Product the underlying Licensed Compound of which is an [* * *] Antibody, and once for each indication for a Licensed Compound or Licensed Product the underlying Licensed Compound of which is a [* * *] Antibody, regardless of how many Licensed Compounds and Licensed Products with such Licensed Compound may achieve the milestone event and regardless of whether the same Licensed Compound or Licensed Product achieves the milestone event for the same indication more than once. By way of a nonlimiting example, if an [* * *] Antibody Licensed Compound and a Licensed Product containing an [* * *] Antibody achieve the same milestone event in the same indication, only one payment is due; if an [* * *] Antibody Licensed Compound and a Licensed Product containing an [* * *] Antibody achieve the same milestone event in the same indication, only one payment is due; and if a [* * *] Antibody Licensed Compound and a Licensed Product containing a [* * *] Antibody achieve the same milestone event in the same indication, only one payment is due. In addition for clarity, if an [* * *] Antibody Licensed Compound or Licensed Product achieves a particular milestone, and an [* * *] ...
Option Compound Development Milestones. For any Licensed Compound or Licensed Product containing an Option Compound which is deemed a Licensed Compound in accordance with Article 7 or a Licensed Product containing such Licensed Compound, Celgene shall pay to Acceleron the amounts set forth below no later than [* * *] after the earliest date on which the corresponding milestone event has first been achieved with respect to any such Licensed Compound or Licensed Product containing an Option Compound (for the avoidance of doubt, the milestones set forth below shall be payable separately with respect to each Option Compound (but not separately for an Option Compound and Licensed Product that contains such Option Compound)): Milestone Event Payment for firstOptionCompoundlicensed toCelgene Payment forsecond OptionCompoundlicensed toCelgene Payment for thirdand succeedingOptionCompoundslicensed toCelgene For clarity, the milestone payments set forth in this Section 5.3 shall be paid only once for each Licensed Compound or Licensed Product the underlying Licensed Compound of which is the same Option Compound, regardless of how many Licensed Compounds and Licensed Products with the same Option Compound may achieve the milestone event and regardless of whether the same Licensed Compound or Licensed Product achieves the milestone event more than once for the same or different indication. By way of a nonlimiting example, if a Licensed Compound and a Licensed Product containing the same Option Compound achieve the same milestone event, only one payment is due. Furthermore, to the extent a Licensed Compound or Licensed Product fails or is discontinued and the Parties agree upon a replacement Licensed Compound or Licensed Product containing the same Option Compound or a back up thereof to be substituted for the original Option Compound, any milestones previously paid for such failed Licensed Compound or Licensed Product shall not be paid a second time with respect to such replacement Licensed Compound or Licensed Product. To the extent that any prior milestone has not been paid at the time of achievement of a subsequent milestone by a Licensed Compound or Licensed Product, then upon the achievement of such subsequent milestone by such Licensed Compound or Licensed Product all preceding unpaid milestone payments for such Licensed Compound or Licensed Product shall be made in addition to the payment corresponding to the milestone that has been achieved; provided that [* * *] shall not be deemed to trigger any m...
Option Compound Development Milestones. Provided that the option in Article 7 is exercised in full, for a Licensed Compound or Licensed Product containing an [* * *] Antibody, [* * *] Antibody, or [* * *] Antibody, Celgene shall also pay to Acceleron the amounts set forth below no later than [* * *] days after the earliest date on which the corresponding milestone event has first been achieved with respect to any such Licensed Compound or Licensed Product (for the avoidance of doubt, the milestones set forth below shall be payable separately with respect to a Licensed Compound or Licensed Product containing an [* * *] Antibody, an [* * *] Antibody or a [* * *] Antibody):
Option Compound Development Milestones. For any Licensed Compound or Licensed Product containing an Option Compound which is deemed a Licensed Compound in accordance with Article 7 or a Licensed Product containing such Licensed Compound, Celgene shall pay to Acceleron the amounts set forth below no later than [* * *] after the earliest date on which the corresponding milestone event has first been achieved with respect to any such Licensed Compound or Licensed Product containing an Option Compound (for the avoidance of doubt, the milestones set forth below shall be payable separately with respect to each Option Compound (but not separately for an Option Compound and Licensed Product that contains such Option Compound)): Milestone Event Payment for first Option Compound licensed to Celgene Payment for second Option Compound licensed to Celgene Payment for third and succeeding Option Compounds licensed to Celgene [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *] [* * *] $[* * *] $[* * *] $[* * *]